MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Bristol-Myers Squibb Co.

Ouvert

SecteurSoins de santé

47.54 -2.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

46.95

Max

48.84

Chiffres clés

By Trading Economics

Revenu

-1.1B

76M

Ventes

442M

12B

P/E

Moyenne du Secteur

14.05

57.333

BPA

1.67

Rendement du dividende

5.04

Marge bénéficiaire

0.616

Employés

34,100

EBITDA

-1.9B

2.6B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+18.22% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

5.04%

2.63%

Date du Prochain Dividende

1 mai 2025

Date du Prochain Détachement de Dividende

4 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-21B

100B

Ouverture précédente

49.6

Clôture précédente

47.54

Score Technique

By Trading Central

Confiance

Neutral Evidence

Bristol-Myers Squibb Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 11:32 UTC

Résultats

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 mars 2025, 10:13 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mars 2025, 10:13 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 14:15 UTC

Actualités
Résultats

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 12:37 UTC

Market Talk
Résultats

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 avr. 2025, 11:17 UTC

Résultats

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 avr. 2025, 11:13 UTC

Actualités
Résultats

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 avr. 2025, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 mars 2025, 09:30 UTC

Actualités

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Comparaison

Variation de prix

Bristol-Myers Squibb Co. prévision

Objectif de Prix

By TipRanks

18.22% hausse

Prévisions sur 12 Mois

Moyen 57.56 USD  18.22%

Haut 70 USD

Bas 36 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

19 ratings

5

Achat

13

Maintien

1

Vente

Score Technique

By Trading Central

47.54 / 48.82Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Bearish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.